沙利度胺联合锝[^(99)Tc]亚甲基二膦酸盐治疗银屑病关节炎患者疗效观察

Effect of thalidomide combined with technetium [^(99)Tc]methylenediphosphonate in patients with psoriatic arthritis

目的观察沙利度胺联合锝[99Tc]亚甲基二膦酸盐治疗银屑病关节炎患者的临床疗效及安全性。方法选取60例银屑病关节炎患者给予沙利度胺联合锝[99Tc]亚甲基二膦酸盐治疗,疗程12周。观察患者的临床治疗效果;比较治疗前与治疗12周后患者的临床症状体征、相关实验室检测指标的变化情况及不良反应发生情况。结果治疗12周后,患者的治疗总有效率为98.33%;患者的PASI评分、HAQ评分、关节压痛指数、关节肿胀指数均明显低于治疗前(P<0.01);患者的血沉(ESR)、C反应蛋白(CRP)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)水平均明显低于治疗前(P<0.01)。治疗过程中患者无严重不良反应发生。结论沙利度胺联合锝[99Tc]亚甲基二膦酸盐治疗银屑病关节炎患者,可取得较好的临床疗效,显著改善患者的临床症状,缓解患者炎症反应,治疗安全性好。

ObjectiveTo observe the clinical efficacy and safety of thalidomide combined with technetium [^99Tc]methylenediphosphonate in patients with psoriatic arthritis. Methods60 cases of patients with psoriatic arthritis were treated with thalidomide combined with technetium [^99Tc] methylenediphosphonate for 12 weeks. Observation of the clinical therapeutic effect of the patients. The clinical symptoms and signs, the changes in related laboratory test indexes of the patients before and after 12 weeks＇ treatment were compared. Observation of the occurrence of adverse reactions. ResultsAfter 12 weeks of treatment, the total effective rate of treatment was 98.33%. The PASI score, HAQ score, joint pressure index, and joint swelling index of the patients were significantly lower than those before the treatment （P〈0.01）. The levels of erythrocyte sedimentation rate, C reactive protein, immunoglobulin A, immunoglobulin G and immunoglobulin M levels were significantly lower than those before treatment （P〈0.01）. There was no serious adverse reaction during the treatment. ConclusionThalidomide combined with technetium [^99Tc] methylenediphosphonate treatment in patients with psoriatic arthritis can get better clinical effect, improve the clinical symptoms, relieve the inflammatory response, and have high safety.